Reference is made to the stock exchange notices from Aqua Bio Technology ASA
("ABTEC") published on 12 February 2026 regarding the successful placement of
a private placement of 2,000,000 new shares in the company, at a subscription
price of NOK 5.00 per share, corresponding to the par value of the shares of
the company following a reverse share split to be implemented prior to formal
completion of the private placement. The following shareholders have had their
holdings diluted as a consequence of the private placement and thereby
surpassed a notifiable threshold. The number of shares has been presented on
the basis of the reverse share split (50:1) having been completed, as this is
intended to be completed prior to the formal completion of the private
placement. Following completion of the private placement, RH Industri AS and
Roger Hofseth will hold 464,355 shares in ABTEC, corresponding to 8.9% of the
shares and votes in the company.
This disclosure is made pursuant to section 4-2 of the Norwegian Securities
Trading Act.
Contacts
Kristian Flaten
CEO & CFO
Aqua Bio Technology ASA
Phone: +47 9509 2322
Email: kf@aquabiotech.no
About Us
Aqua Bio Technology ASA (ABTEC) is a technology and distribution group in
skincare and nonfood. The group has distribution towards B2C and B2B, and
offers freight, customs, and logistics services. The group also develops
sustainable biotechnology for use in skincare products. Aqua Bio Technology is
listed on Euronext Expand Oslo.
This notice is published by Kristian Flaten on the listed date and time.
This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 17. The information was submitted for publication,
through the agency of the contact persons set out above, at 2026-02-15 23:25
CET.